Hua Zhong

Sun Yat-sen University — China

Medicine · Health Sciences

26h-index6.1kcitations113works3.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(28), Lung Cancer Treatments and Mutations(26), Hepatitis C virus research(9), Hepatitis B Virus Studies(9), Cancer-related molecular mechanisms research(9)

Publications113 total

Prognostic Significance of Eosinophil Extracellular Traps in Chronic Rhinosinusitis and Innovative Nanosheets‐Based Clearance Therapy
Clinical & Experimental Allergy·2026
Proteome-wide association study of prostate cancer risk across populations
Nature Communications·2025Open Access
Review of clinical medication adherence in patients with schizophrenia
World Journal of Psychiatry·2025Open Access
Mechanisms of multi-species mealybug invasions in Hainan Island of China: Integrating niche, distribution, and habitat drivers
PLoS ONE·2025Open Access
[Interpretation of the Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2025 edition)].
PubMed·2025
P1.11.83 Ivonescimab Versus Pembrolizumab for PD-L1-Positive NSCLC: A Subgroup Analysis of HARMONi-2 by Tumor Histology
Journal of Thoracic Oncology·2025
First-line therapy of osimertinib with chemotherapy in Chinese patients with EGFR mutation–positive non–small cell lung cancer: protocol for a multicenter, prospective, observational study
Frontiers in Oncology·2025Open Access
OX40–heparan sulfate binding facilitates CAR T cell penetration into solid tumors in mice
Science Translational Medicine·2025· 5 cited
Synthetic Lethal Co-Mutations in DNA Damage Response Pathways Predict Response to Immunotherapy in Pan-Cancer
JCO Precision Oncology·2025· 2 citedOpen Access
Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC
Annals of Medicine·2025· 2 citedOpen Access
Noscapine derivative 428 suppresses ferroptosis through targeting GPX4
Redox Biology·2025· 2 citedOpen Access
Noscapine Derivative 428 Suppresses Ferroptosis Through Targeting Gpx4
SSRN Electronic Journal·2025Open Access
Osimertinib for <scp>EGFR</scp>‐Mutant <scp>NSCLC</scp> Patients With Acquired <scp>T790M</scp> and <scp>EGFR</scp> Amplification After First‐Generation <scp>EGFR</scp>‐<scp>TKI</scp> Resistance
Cancer Science·2024· 3 citedOpen Access
Impact of &lt;i&gt;PD-L1&lt;/i&gt; Gene Polymorphisms and Interactions with Cooking with Solid Fuel Exposure on Tuberculosis
Public Health Genomics·2024Open Access
Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer
Journal for ImmunoTherapy of Cancer·2024· 14 citedOpen Access
Abstract 5352: SOX9-dependent immune microenvironment remodeling drives KRAS-induced lung adenocarcinoma progression
Cancer Research·2024
81P Single-cell and bulk RNA sequencing analysis of the pan-cancer immune microenvironment identifies a novel tumor-associated macrophage signature predicting immunotherapy response
ESMO Open·2024Open Access
13P Tislelizumab (TIS) plus chemotherapy (chemo) with or without bevacizumab (beva) for patients with EGFR-mutated nonsquamous non-small cell lung cancer (nsq-NSCLC) after progression on EGFR tyrosine kinase inhibitor (TKI) therapy
ESMO Open·2024Open Access
70P Combination of EGFR-TKI and chemotherapy versus EGFR-TKI monotherapy as neoadjuvant treatment of stage III-N2 EGFR-mutant non-small cell lung cancer
ESMO Open·2024Open Access
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial
The Lancet Respiratory Medicine·2024· 47 cited
page 1 of 6Next →

Frequent Co-authors

Baohui Han(14), Wei Nie(10), Runbo Zhong(8), Shuhui Cao(7), Jun Lü(7), Jonathan W. Simons(6), Yuqing Lou(5), Xueyan Zhang(5), Yan Zhou(5), Yanwei Zhang(4), Kai Gu(4), Yue Wang(4), Qing Lv(3), Wenbin Ye(3), Yaou Zhang(3), Jie Qian(3), Midie Xu(3), Lu Gan(3), Fang Hu(3), Changhui Li(3)